Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus
- PMID: 27832452
- PMCID: PMC5425330
- DOI: 10.1007/s40262-016-0472-6
Clinical Pharmacokinetics and Pharmacodynamics of Antihyperglycemic Medications in Children and Adolescents with Type 2 Diabetes Mellitus
Abstract
The incidence of type 2 diabetes mellitus (T2DM) among children and adolescents has been rising. This condition is associated with obesity, and it's prevalence is higher among minority or female youth. Lifestyle modification including diet and exercise is only successful in a small proportion of patients; therefore, pharmacotherapy approaches are needed to treat T2DM among youth. Currently, in the USA, only metformin and insulin are approved for the treatment of T2DM in children. However, several antihyperglycemic agents including exenatide, glimepiride, glyburide, liraglutide, pioglitazone, and rosiglitazone are also used off-label in this population. Moreover, a number of clinical trials are ongoing that are aimed at addressing the safety and efficacy of newer antihyperglycemic agents in this population. Little is known about the safety, efficacy, or pharmacokinetics of antihyperglycemic agents in children or adolescents. Our ability to predict the pharmacokinetics of these agents in youth is hampered first by the lack of information about the expression and activity of drug-metabolizing enzymes and transporters in this population and second by the presence of comorbid conditions such as obesity and fatty liver disease. This article reviews the prevalence of obesity and T2DM in children and adolescents (youth). We then summarize published studies on safety and effectiveness of antihyperglycemic medications in youth. Drug disposition may be affected by age or puberty and thus the expression and activity of different pathways for drug metabolism and xenobiotic transporters are compared between youth and adults followed by a summary of pharmacokinetics studies of antihyperglycemic agents currently used in this population.
Conflict of interest statement
Figures
Similar articles
-
Metformin prescription patterns among US adolescents aged 10-19 years: 2009-2013.J Clin Pharm Ther. 2016 Apr;41(2):229-36. doi: 10.1111/jcpt.12379. Epub 2016 Mar 9. J Clin Pharm Ther. 2016. PMID: 26960965
-
Advances in the treatment of type 2 diabetes mellitus.Am J Ther. 2011 Mar-Apr;18(2):117-52. doi: 10.1097/MJT.0b013e3181afbf51. Am J Ther. 2011. PMID: 19834322 Review.
-
Drugs for the treatment of pediatric type 2 diabetes mellitus and related co-morbidities.Expert Opin Pharmacother. 2016 Dec;17(18):2449-2460. doi: 10.1080/14656566.2016.1258057. Epub 2016 Nov 21. Expert Opin Pharmacother. 2016. PMID: 27819155 Review.
-
Cardiovascular benefits and safety of non-insulin medications used in the treatment of type 2 diabetes mellitus.Postgrad Med. 2017 Nov;129(8):811-821. doi: 10.1080/00325481.2017.1358064. Epub 2017 Jul 27. Postgrad Med. 2017. PMID: 28749197 Review.
-
The pharmacokinetics and pharmacodynamics of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.Eur J Clin Pharmacol. 2017 Mar;73(3):279-288. doi: 10.1007/s00228-016-2175-1. Epub 2016 Dec 20. Eur J Clin Pharmacol. 2017. PMID: 27999883 Free PMC article. Clinical Trial.
Cited by
-
Improvement of high-glucose and insulin resistance of chromium malate in 3T3-L1 adipocytes by glucose uptake and insulin sensitivity signaling pathways and its mechanism.RSC Adv. 2018 Dec 21;9(1):114-127. doi: 10.1039/c8ra07470d. eCollection 2018 Dec 19. RSC Adv. 2018. PMID: 35521592 Free PMC article.
-
High Concentrations of Rosiglitazone Reduce mRNA and Protein Levels of LRP1 in HepG2 Cells.Front Pharmacol. 2017 Nov 14;8:772. doi: 10.3389/fphar.2017.00772. eCollection 2017. Front Pharmacol. 2017. PMID: 29201005 Free PMC article.
-
Experience with enteral sulfonylurea monotherapy for extremely low birth weight infants with hyperglycemia.Clin Pediatr Endocrinol. 2022;31(4):225-233. doi: 10.1297/cpe.2022-0018. Epub 2022 Jun 30. Clin Pediatr Endocrinol. 2022. PMID: 36405438 Free PMC article.
-
The identification of gene signature and critical pathway associated with childhood-onset type 2 diabetes.PeerJ. 2019 Feb 6;7:e6343. doi: 10.7717/peerj.6343. eCollection 2019. PeerJ. 2019. PMID: 30755828 Free PMC article.
-
Effects of genetic variants of organic cation transporters on metformin response in newly diagnosed patients with type 2 diabetes.Medicine (Baltimore). 2024 Nov 29;103(48):e40684. doi: 10.1097/MD.0000000000040684. Medicine (Baltimore). 2024. PMID: 39612420 Free PMC article.
References
-
- Rosenbloom AL, Joe JR, Young RS, Winter WE. Emerging epidemic of type 2 diabetes in youth. Diabetes Care. 1999 Feb;22(2):345–54. - PubMed
-
- Gaylor AS, Condren ME. Type 2 diabetes mellitus in the pediatric population. Pharmacotherapy. 2004 Jul;24(7):871–8. - PubMed
-
- Horta BL, Loret de Mola C, Victora CG. Long-term consequences of breastfeeding on cholesterol, obesity, systolic blood pressure and type 2 diabetes: a systematic review and meta-analysis. Acta Paediatr. 2015 Dec;104(467):30–7. - PubMed
-
- Whincup PH, Kaye SJ, Owen CG, Huxley R, Cook DG, Anazawa S, et al. Birth weight and risk of type 2 diabetes: a systematic review. JAMA. 2008 Dec 24;300(24):2886–97. - PubMed
-
- Mayer-Davis EJ. Type 2 diabetes in youth: epidemiology and current research toward prevention and treatment. J Am Diet Assoc. 2008 Apr;108(4 Suppl 1):S45–51. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical